Immutep Limited's latest marketcap:
As of 10/14/2026, Immutep Limited's market capitalization has reached $26.76 M. According to our data, Immutep Limited is the 35512th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 26.76 M |
| Revenue (ttm) | 13.79 M |
| Net Income (ttm) | -54,863,067 |
| Shares Out | 1.47 B |
| EPS (ttm) | -0.04 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 09/01/2026 |
Immutep Limited's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 10/14/2026 | $26.76 M | -94.04% | 35512 |
| 12/31/2025 | $417.7 M | 32.52% | 18085 |
| 12/31/2024 | $315.2 M | 10.6% | 16088 |
| 12/29/2023 | $285 M | 87.99% | 16762 |
| 12/30/2022 | $151.6 M | -38.22% | 19693 |
| 12/31/2021 | $245.4 M | 60.29% | 17654 |
| 12/31/2020 | $153.1 M | 152.22% | 18173 |
| 12/31/2019 | $60.7 M | 8.98% | 20833 |
| 12/31/2018 | $55.7 M | 70.34% | 20368 |
| 12/29/2017 | $32.7 M | 125.52% | 23582 |
Company Profile
About Immutep Limited
Immutep Limited is a late-stage biotechnology company focused on developing innovative LAG-3 related immunotherapies for cancer and autoimmune diseases. Headquartered in Sydney, Australia, the company was incorporated in 1987 and rebranded from Prima BioMed Ltd in November 2017.
Key Product Candidates
- Eftilagimod Alpha (Efti/IMP321): A soluble LAG-3lg fusion protein in clinical development for various cancers.
- TACTI-004: Phase III trial for first-line non-small cell lung cancer (1L NSCLC).
- TACTI-003: Phase IIb trial for first-line head and neck squamous cell carcinoma (HNSCC).
- TACTI-002: Phase II trial for NSCLC and HNSCC.
- AIPAC-003: Phase II/III trial for metastatic breast cancer.
- EFTISARC-NEO: Phase II trial for soft tissue sarcoma.
Additional Pipeline Highlights
- INSIGHT-003: Phase I trial for 1L NSCLC and solid tumors.
- INSIGHT-005: Phase I trial for metastatic urothelial cancer.
- IMP761: Preclinical trial for autoimmune diseases.
- LAG525: Phase II trial for solid tumors, blood cancer, triple-negative breast cancer, and melanoma; Phase I for triple-negative breast cancer.
Strategic Collaborations
Immutep has established partnerships with leading pharmaceutical and research organizations, including:
- Merck & Co., Inc.
- GlaxoSmithKline
- EOC Pharma
- Novartis
- Laboratory Corporation of America Holdings
Frequently Asked Questions
-
What is Immutep Limited's (IMMP) current market cap?As of 10/14/2026, Immutep Limited (including the parent company, if applicable) has an estimated market capitalization of $26.76 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Immutep Limited (IMMP) rank globally by market cap?Immutep Limited global market capitalization ranking is approximately 35512 as of 10/14/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.